Jan 15 (Reuters) - OBSEVA SA:
* PHASE 3 LINZAGOLIX TRIALS EXPECTED TO GENERATE ADDITIONAL DATA IN UTERINE FIBROIDS IN Q2:20 WITH FIRST LINZAGOLIX REGULATORY FILING PLANNED FOR LATE 2020
* ENROLLMENT OF LINZAGOLIX US AND EU PHASE 3 TRIALS IN ENDOMETRIOSIS ON TRACK
* PHASE 2 RESULTS OF OBE022 EXPECTED IN 2H:20 Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Our Standards: The Thomson Reuters Trust Principles.